Strategic Shape Diagnostic
Single Asset
One lead program defines the company. If the lead fails, the company is over. Transaction value hinges entirely on that asset’s stage, data quality, and competitive position. This is the simplest shape to classify — but also the one most likely to be misrepresented as something broader. Counterparties will price it accordingly, and the deal structures available to a Single Asset company are narrower than most founders expect.
Deal Structures
How this shape transacts
Asset-specific licensing, typically single-program out-licensing to a larger pharma or biotech partner
Milestone-heavy term structures with limited upfront exposure for the acquirer
Outright acquisition when the asset reaches a de-risking inflection (Phase 2 data, pivotal readout, or regulatory clearance)
Contradictions
Common contradictions for SA companies
Contradiction 01
Claiming platform breadth with single-asset evidence — the deck describes a pipeline, but the data, capital allocation, and IP all point to one program
Contradiction 02
Mismatched capital plan — raising platform-scale capital for a single-asset development trajectory, which signals misunderstanding of the company’s actual economics
Contradiction 03
Describing the company as “early-stage platform” when no second program has advanced past target identification
Counterparty View
What counterparties expect
Pharma BD teams evaluating SA companies apply milestone-heavy structures with significant downside protection. Upfront payments are calibrated to the asset’s stage and competitive position, not to the company’s narrative about what it could become. Counterparties expect clean data packages, clear regulatory paths, and realistic development timelines. The premium available to an SA company is entirely a function of clinical evidence quality.
Find out if this is your shape.
The Shape Diagnostic classifies your company into one of seven archetypes in seven minutes.
Free classification · $49 full report